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ABSTRACT
Objective. Chronic nasal carriage of Staphylococcus aureus (SA) increases the risk
of relapse while Rituximab (RTX) is an effective agent for inducing and maintaining
remission in patients with Granulomatosis with polyangiitis (GPA). We investigated
whether B cell depletion and hypogammaglobulinemia that occur during RTX treat-
ment increase the risk of chronic SA nasal carriage and subsequent disease flares, in
GPA patients on long-term RTX maintenance therapy.
Methods. Retrospective cohort study from a disease registry involving 29 GPA pa-
tients receiving RTX maintenance (median RTX dose of 9 g) during a median period
of 49 months. Nasal swabs were collected prior and during RTX for a median of 3 and
9 swabs respectively. Persistent SA nasal carriage was defined with the presence of SA
in more than 75% of nasal swabs.
Results. SA nasal carriage did not change during RTX (p = 0.297). However, the rate
of positive nasal swabs in GPA patients with transient SA nasal carriage during RTX
maintenance increased from 0 prior RTX to 0.42 during RTX (p = 0.017). Persistent
SA nasal carriage did not increase the risk of relapses (p = 0.844), of hypogamma-
globulinemia (p = 0.122) and of severe infections (p = 0.144), but reduced the risk
of chronic infections (p = 0.044). Change in SA carriage status during RTX did not
influence the risk of relapses (p = 0.756), hypogammaglobulinamia (p = 0.474) and
infections, either severe (p = 0.913) or chronic (p = 0.121).
Conclusion. Long-term RTX maintenance therapy in GPA patients did not
significantly influence SA nasal carriage status. Persistent SA carriage during
long-term RTX treatment did not seem to increase the risk of relapses, but seemed to
decrease the risk of hypogammaglobulinemia associated chronic infections.
Subjects Allergy and Clinical Immunology, Immunology, Infectious Diseases, Internal Medicine,
Rheumatology
Keywords Rituximab, Granulomatosis with polyangiitis, Vasculitis, Relapse, Infections,
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INTRODUCTION
Granulomatosis with polyangiitis (GPA) is a clinicopathologic variant of antineutrophil
cytoplasmic antibodies (ANCA)-associated vasculitis (AAV). It is characterized by
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a necrotizing granulomatous inflammation usually involving the upper and lower
respiratory tract, a necrotizing vasculitis affecting predominantly small to medium vessels
and commonly a necrotizing glomerulonephritis, often in the presence of Proteinase 3
(PR3)-ANCA (Jennette et al., 2012). The aetiology of GPA is unknown; but infections and
in particular nasal carriage of Staphylococcus aureus (SA) have been implicated (Tadema,
Heeringa & Kallenberg, 2011). SA nasal carriage may trigger GPA through staphylococcal
superantigens, molecular mimicry, increased Toll-like receptor signalling in leukocytes and
the induction of neutrophil extracellular traps (NETs) (Tadema, Heeringa & Kallenberg,
2011). SA interacts with endothelial, T and B cells creating an inflammatory milieu and
activating neutrophils locally responsible of damage by release of proteolytic enzymes
and reactive oxygen species (Popa & Tervaert, 2003). SA can evade innate immunity by
resisting phagocytosis and can survive inside neutrophils (Foster, 2005). SA can also evade
induced immunity since SA can deplete potential antibody-secreting B cells and inhibit
proliferation of antigen-specific T cells (Foster, 2005). GPA patients have an abnormal
epithelial nasal barrier with an altered basal cytokine expression and a reduced secretion of
interleukin-8 upon SA stimulation that could facilitate nasal carriage (Wohlers et al., 2012).
SA permanently colonises the anterior nares of 20% of the population while transient
colonisation occurs in another 60% (Peacock, de Silva & Lowy, 2001). In one study, GPA
patients have a slightly increased rate of SA nasal carriage (72%), compared to Rheumatoid
Arthritis patients (46%) and hospital staff members (58%) (Laudien et al., 2010). The risk
of disease relapses in GPA increases with SA nasal carriage (Laudien et al., 2010) and is 7
times higher with chronic SA nasal carriage (Stegeman et al., 1994). Antibiotic prophylaxis
with Trimethoprim-sulfamethoxazole (TMP-SMX) can decrease the risk of relapse by 60%
and of infections in GPA (Stegeman et al., 1996; Zycinska et al., 2009), although the basis for
this is unclear since TMP-SMX antibiotic prophylaxis does not eliminate SA nasal carriage
in GPA (Wohlers et al., 2012; Popa et al., 2007).
While immunosuppressive drugs (ID) are the mainstay of therapy in GPA, B cell
depleting therapy with rituximab (RTX) has proven very effective in inducing (Jones
et al., 2010; Stone et al., 2010) and maintaining remission in GPA (Smith et al., 2012;
Cartin-Ceba et al., 2012; Besada, Koldingsnes &h Nossent, 2013). However, side effects of
B cell depletion over time such as the reduction in all immunoglobulins (Ig) class levels
(Besada, Koldingsnes &h Nossent, 2013) could potentially increase the risk of SA carriage.
Our study investigated if long-term RTX maintenance treatment increases the risk
of SA carriage in GPA patients and if SA carriage promoted relapses, infections and/or
hypogammaglobulinemia.
PATIENTS AND METHODS
Since 2001 our vasculitis disease registry (Nordnorsk Vaskulittregister) has collected infor-
mation on disease presentation and course from patients with an established diagnosis of
primary vasculitis followed at the University Hospital of North Norway. All patients gave
informed written consent at registry inclusion according to the declaration of Helsinki.
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All patients satisfied the American College of Rheumatology 1990 classification and/or
Chapel Hill consensus conference criteria (Jennette et al., 1994; Leavitt et al., 1990).
Twenty-nine GPA patients from that registry who received long-term RTX treatment
with a RTX cumulative dose of 5 g or more before September 2011 were included in
the study. Eighty-six percent received RTX for relapse and 14% for new disease. RTX
treatment was initiated as two 1-gram infusions 2 weeks apart with co-administration
of methylprednisolone 125 mg, paracetamol 1,000 mg and either cetirizine 10 mg or
polaramine 4 mg (RA protocol). Due to the observed RTX efficacy and the relapsing nature
of GPA, RTX was then re-administered pre-emptively either as 2 g infusion (1 g twice
during a fortnight) annually or as 1 g infusion biannually (1 g every 6 months). RTX was
added to other ID (other than prednisolone) in 27 patients (93%), while 2 (7%) received
RTX in monotherapy. The timing and pace of ID discontinuation was at the discretion of
the treating physician, whereas the oral daily prednisolone dose (ODPD) was tapered and
discontinued in a controlled manner.
Antibiotic prophylaxis against relapse with TMP-SMX (dose 320 mg of TMP
and 1,600 mg of SMX daily) was not blinded and was at the physician’s discretion.
Ciprofloxacin (dose ranging from 500 to 1,000 mg daily) was used in case of sulfamide
allergy, poor TMP-SMX tolerance or concomitant methotrexate use. Compliance
of antibiotic prophylaxis was assessed during patients’ visits. We defined antibiotic
prophylaxis as the use of antibiotic prophylaxis for more than 50% of the time during
long-term RTX maintenance.
Nasal swabs were performed biannually in one anterior naris by firmly rotating the
sterile cotton-swab. Similar to the study of Stegeman et al. (1994), we defined patients with
positive SA nasal carriage as either transient or persistent if SA was present in respectively
less than 75% and more than 75% of all the nasal swabs. We defined patients as non-SA
carriers when none of the nasal swabs grew SA.
Fixed set of blood tests (ANCA levels, quantification of immunoglobulin classes
and flow cytometric immunophenotyping of lymphocytes) were performed prior RTX
initiation and before each new re-treatment until either 30th September 2011 (closing date
of this study) or shortly before the administration of intravenous immunoglobulins (IVIG)
due to hypogammaglobulinemia and/or infections. CD4 cell counts and serum total Ig lev-
els taken after the administration of 2 g of RTX and at last visit were included in the study.
Relapses were defined by the recurrence, worsening or first appearance of one or more
BVAS items attributable to GPA after remission. Hypogammaglobulinemia was defined as
serum total Ig < 6 g/L. Severe infections were defined as if hospitalisation and intravenous
antibiotic treatment were necessary, while chronic infections were defined as symptomatic
infections mostly localised in the ear-nose-throat (ENT) and respiratory tract, lasting 3
months or more and requiring several antibiotic courses.
Data were analysed with SPSS version 20.0 (SPSS Ltd, Chicago, Ilinois, USA).
Descriptive statistics were used to describe SA nasal carriage during RTX maintenance.
Continuous variables were expressed in median and range; categorical variables were
expressed in number and percentage. Related-samples Wilcoxon signed rank test was
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used to test for difference between rates of positive SA nasal swabs prior RTX and during
maintenance. Chi-square and Kruskal Wallis tests were used appropriately for subgroups
analysis concerning SA nasal carriage status. SA nasal carriage, change in SA carriage status
and antibiotic prophylaxis during RTX maintenance were analysed by Kaplan–Meier
survival curves as risk factors of relapse, infections and RTX discontinuation due to
hypogammaglobulinemia. P-values <0.05 were considered significant.
RESULTS
Patients’ characteristics
Twenty-nine GPA patients (52% men) with a median age of 50 years (19–75) received
RTX. 90% of the patients were ANCA positive at diagnosis: 86% PR3-ANCA and 3%
MPO-ANCA positive. 59% had renal involvement; 66% had pulmonary involvement
and 62% had orbital-subglottic involvement. At RTX initiation, their disease duration
was 57 (22–70) months and they had received a cumulative dose of 17 (0–250) g
cyclophosphamide.
GPA patients received a cumulative RTX dose of 9 g (5–13) for remission induction and
maintenance during 49 (19–88) months. Twelve patients (41%) received the 1 g biannually
regimen, 6 (21%) received the 2 g annually regimen and 11 (38%) alternated between
regimens. RTX was added to other ID (other than prednisolone) in 27 patients (93%),
which was continued during 24 months (1–54) after RTX initiation. ODPD decreased
from 23 (0–60) at baseline to 5 (0–15) mg at last visit. Six patients (21%) discontinued
prednisolone 23 months (7–55) after RTX initiation.
Nasal carriage during RTX maintenance
Three (1–8) nasal swabs were analysed before RTX and 9 (2–22) during RTX maintenance.
The number of nasal swabs did not differ between the different SA carriage groups before
and during RTX (respectively p = 0.411 and p = 0.437).
Before RTX initiation, 13 patients (52%) were non-SA carriers, but 2 patients had
positive swabs for other bacteria (Table 1). Seven patients (28%) had transient SA nasal
carriage and 5 (20%) had persistent carriage before RTX. During RTX maintenance,
9 patients (31%) were non-SA carriers, while 12 (41%) had transient carriage and 8
(28%) had persistent nasal carriage. Ten (40%) patients did not change SA carriage status
during RTX maintenance, while 11 (44%) increased nasal SA carriage status and 4 (16%)
decreased during RTX maintenance. The frequency of SA nasal carriage did not differ
significantly before and during RTX (p = 0.297) (Table 1). However, the rate of positive
nasal swabs in GPA patients with transient SA nasal carriage during RTX maintenance
(n = 11) increased from 0 prior RTX to 0.42 during RTX (p = 0.017 after square root
transformation).
The nasal swabs identified several other bacteria at initiation and during RTX
maintenance (Table 1). Of interest, 7 (24%) and 4 (14%) GPA patients had respectively
Streptococcus pneumoniae and Haemophilus influenzae at least once in their nasal swabs
during RTX maintenance. S. pneumoniae and SA were often identified together at last visit,
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Table 1 Staphylococcus aureus and other bacteria nasal carriage before and during rituximab main-
tenance in granulomatosis with polyangiitis patients.
Prior RTX (25)a During RTX (29) p
Staphylococcus aureus 0.297
Persistent carriage 5 (20) 8 (28)
Transient carriage 7 (28) 12 (41)
Non carrier 13 (52) 9 (31)
Haemophilus influenza 0 4 (14) NA
Streptococcus pneumonia 1 (4) 7 (24) NA
Other bacteria 1 (4)b 2 (7)c NA
Notes.
RTX: rituximab Results are expressed in absolute numbers (percentage) and significance is determined by Chi-squared
test for association.
a No nasal swabs results were recorded in 4 patients.
b One patient had Pseudomonas aeruginosa prior to RTX.
c One patient had Pseudomonas aeruginosa in 2 nasal swabs and one patient had Neisseria species found in one
nasal swab.
whereas H. influenzae was identified in 2 out of 8 patients who discontinued RTX due to
hypogammaglobulinemia at the time of its discontinuation.
SA nasal carriage
GPA patient characteristics differed in relation to SA nasal carriage. SA non-carriers
had less lung involvement (p = 0.047) and seemed to receive higher ODPD at baseline
(p = 0.141) compared with patients with either transient or persistent nasal carriage
(Table 2). On the other hand, patients with persistent SA nasal carriage had received 55 g of
CYC compared with 13 g in the other 2 subgroups (p = 0.163). The use of other ID during
RTX treatment was similar within the different SA nasal carriage subgroups (Table 2).
Risk of relapse
During RTX maintenance, 9 relapses occurred in 8 patients (28%) and 2 thirds of the
relapses involved the respiratory tract and ENT. Three patients (38%) who relapsed had
persistent SA nasal carriage (Table 2). The lone patient who relapsed twice did not carry
SA. There was no association between SA nasal carriage and either overall frequency of
relapses (p = 0.243) (Table 2) or time-adjusted risk of relapse (p = 0.844) (Fig. 1A).
There was no association between change of SA nasal carriage status during RTX and
time-adjusted risk of relapse (p = 0.756) (Fig. 2A).
Risk of infections
During RTX maintenance, severe and chronic infections developed in 7 and 9 patients
respectively.
Seven patients developed severe infections, but there was no association between SA
carriage and the frequency (p = 0.213) (Table 2) or time-adjusted risk (p = 0.144) (Fig. 1B)
of severe infections. There was no association between change of SA nasal carriage status
during RTX and time-adjusted risk of relapse (p = 0.913) (Fig. 2B).
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Male 5 (56) 5 (42) 5 (62) 0.634
Age at baseline (y) 54 43 44 0.375
Kidney involvement 5(56) 6(50) 6(75) 0.525
Lung involvement 3(33) 10(83) 6(75) 0.047
Orbital-subglottic involvement 4(44) 9(75) 5(63) 0.361
PR3-ANCA 8(89) 10(83) 7(88) 0.414
BVAS at baseline 11 10 10 0.382
RTX maintenance duration (w) 173 182 170 0.305
CYC cumulative dose (g) 13 13 55 0.163
RTX cumulative dose (g) 8 9.5 8 0.468
1 g biannually regimen 6(67) 3(25) 3(38) 0.153
MTX use during RTX 3(33) 4(33) 4(50) 0.711
AZA use during RTX 3(33) 3(25) 2(25) 0.898
MMF use during RTX 1(11) 5(42) 2(25) 0.295
CYC use during RTX 3(33) 3(25) 3(38) 0.891
Total Ig at baseline (g/L) 11 8.5 11 0.278
Total Ig after RTX 2 g (g/L) 8.1 7.5 9.4 0.730
CD4 at baseline (×109/L) 0.39 0.40 0.27 0.538
CD4 after RTX 2g (×109/L) 0.28 0.45 0.39 0.071
Total Ig decline after RTX 2 g (g/L) 3.5 1.4 1.9 0.079
Total Ig overall decline during RTX 5.1 2.5 3.4 0.063
TMP-SMX during RTX 3(33) 3(25) 0 0.212
Ciprofloxacin during RTX 2(22) 3(25) 2(25) 0.987
Severe infections 3(33) 1(8) 3(38) 0.243
Chronic infections 4(44) 5(42) 0 0.082
Relapses 2(22) 3(25) 3(38) 0.754
RTX discontinuation due to
hypogammaglobulinemia
4(44) 2(17) 2(25) 0.364
Notes.
AZA, azathioprine; BVAS, Birmingham vasculitis activity score; CD, cluster of differentiation; CYC, cyclophosphamide; Ig, immunoglobulins; MMF, mycophenolate
mofetil; MTX, methotrexate; PR3-ANCA, proteinase 3 antineutrophil cytoplasmic antibodies; RTX, rituximab; SA, Staphylococcus aureus; TMP-SMX, trimethoprim-
sulfamethoxazole.
Results are expressed in medians for continuous variables and in absolute numbers (percentages) for categorical variables. Difference is determined by Kruskal Wallis
Test for continuous variables and Chi-square test for categorical variables.
Nine patients had chronic infections; however, none of these patients had persistent SA
nasal carriage (p = 0.082) (Table 2). Patients with persistent SA nasal carriage and patients
with an increase of SA nasal carriage status seemed to have a lower time-adjusted risk of
developing chronic infections (respectively p = 0.044 and p = 0.125) (Figs. 1C and 2C). Of
interest, CD4 cell count seemed to increase in persistent and transient carriers, but seemed
to decrease in non-carriers following the first 2 g of RTX (p = 0.071) (Table 2).
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Figure 1 Kaplan-Meier analysis of the probability of relapse (A), severe (B) and chronic (C) infections and discontinuation due to hypogamma-
globulinemia (D) according to Staphylococcus aureus nasal carriage status.
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Figure 2 Kaplan-Meier analysis of the probability of relapse (A), severe (B) and chronic (C) infections and discontinuation due to hypogamma-
globulinemia (D) according to change in Staphylococcus aureus nasal carriage status.
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Risk discontinuing RTX due to hypogammaglobulinemia
Eight patients discontinued RTX due to hypogammaglobulinemia with a level of serum
total Ig of 4.7 (3.5–5.5) g/L. Four patients (50%) had persistent or transient SA nasal
carriage, while 4 patients (50%) did not carry SA (Table 2). Patients with transient SA
nasal carriage had a tendency to lower time-adjusted risk of discontinuing RTX due
to hypogammaglobulinemia, although this was not statistically significant (p = 0.122)
(Fig. 1D). Change in SA nasal carriage status during RTX did not influence the risk of
discontinuing RTX due to hypogammaglobulinemia (p = 0.474) (Fig. 2D).
Non-SA carriers had a tendency to more profound decline of serum total Ig both after
the first 2 g of RTX (p = 0.079) and during RTX maintenance (p = 0.063) compared with
patients with either transient or persistent SA carriage (Table 2).
TMP-SMX and ciprofloxacin during RTX
Before RTX initiation, most patients (90%) had received antibiotic prophylaxis with either
TMP-SMX or ciprofloxacin at some point during the course of their disease. However, only
16 patients (55%) received TMP-SMX antibiotic prophylaxis during RTX maintenance
and just 6 (21%) used TMP-SMX for more than 50% of the time. Similarly, 10 patients
(35%) received ciprofloxacin during RTX maintenance and 7 (24%) used it for more
than 50% of the time. Two patients (7%) switched from ciprofloxacin to TMP-SMX,
while no patients switched from TMP-SMX to ciprofloxacin during RTX maintenance.
The first patient switched when methotrexate was discontinued. The other switched with
the intention of preventing relapse when mycophenolate mofetil was discontinued (even
though the nasal swab was negative). ODPD, CYC cumulative dose and concomitant use of
ID during RTX maintenance did not differ between patients receiving either TMP-SMX or
ciprofloxacin and patients not receiving antibiotics.
During RTX treatment, none of the six GPA patients who used TMP-SMX for more
than 50% of the time had persistent SA nasal carriage and three (50%) were non-SA
carriers. In the ciprofloxacin group, 2 (29%) had persistent SA nasal carriage and 2
(29%) were non-SA carriers. Patients who used TMP-SMX for more than 50% of the
time during RTX maintenance had an increased risk to hypogammaglobulinemia leading
to RTX discontinuation (p = 0.046) (Fig. 3A). On the other hand, none of the patients
using ciprofloxacin for more than 50% of the time during RTX maintenance seemed to
discontinue RTX due to hypogammaglobulinemia (p = 0.065) (Fig. 3B). There were no
significant differences for the risk of severe infections, chronic infections and relapses risks
in patients on or off antibiotic prophylaxis (with either TMP-SMX or ciprofloxacin) (data
not shown).
DISCUSSION
The rate of persistent SA nasal carriage did not change significantly in GPA patients
during long-term RTX treatment, even though SA nasal carriage seemed to increase
in patients with transient carriage. Persistent SA nasal carriage was not a risk factor for
disease relapses, but was associated with a lower frequency of chronic infections. On the
other hand, non-SA carriers seemed to have lower CD4 counts and a steeper decline of
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Figure 3 Kaplan-Meier analysis of the probability of hypogammaglobulinemia according to Trimethoprim-sulfamethoxazole (TMP-SMX) (A)
and ciprofloxacin (B) antibiotic prophylaxis during rituximab maintenance.
total Ig after 2 g of RTX and were more prone to infections and to discontinue RTX due to
hypogammaglobulinemia.
Contrary to the seminal study of Stegeman et al. (1994), persistent SA nasal carriage
did not increase the risk of relapse in GPA patients whilst on treatment with RTX. This
may be due to the lower overall frequency of SA carriers in this cohort since 63% were
persistent SA nasal carriers in the Stegeman study (Stegeman et al., 1994), but only 20%
and 28% persistently carried SA in our cohort before and during RTX maintenance,
respectively. Nasal swabs procedure and inclusion as well as patient selection bias could
explain the difference. Nasal swabs were performed unilaterally in our study and bilaterally
in the study of Stegeman et al. (1994). Nasal swabs of GPA patients receiving prolonged
antibiotics defined as more than 6 weeks were excluded in the study of Stegeman et al.
(1994), whereas all nasal swabs in our study were included with or without concomitant
antibiotics. Also while Stegeman et al. (1994) enrolled all consecutive patients diagnosed
with GPA over a 3.5 years period, our study included consecutive GPA patients receiving
long-term RTX maintenance, who had been mostly refractory to conventional therapy.
The frequency of severe infections was equal in persistent and non-SA carriers, but the
risk of chronic infections during RTX treatment seemed lower in persistent SA carriers
and in patients with increased SA nasal carriage status. In healthy individuals, persistent
SA nasal carriers have a higher risk of infection (Johannessen, Sollid & Hanssen, 2012) than
transient and non-carriers who eradicate SA faster due to stronger anti-staphylococcal
antibodies response (Van Belkum et al., 2009). In our study, non-SA carriers paradoxically
seemed to have a more profound decline of total serum Ig and CD4 cell count already after
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2 g of RTX, indicating an early effect of RTX on the ability to mount an effective immune
response in non-SA carriers.
In healthy individuals, SA carriage also influences the nasal microbiome and inhibits
colonisation from other bacteria (Johannessen, Sollid & Hanssen, 2012). Consequently,
persistent SA nasal carriage in GPA patients receiving long-term RTX could prevent
colonisation from other bacteria and chronic infections due to the continuing interplay
between SA and the immune system.
In our selected cohort of closely followed GPA patients, antibiotic prophylaxis was
neither universal nor continuous and this reflects the uncertainties regarding this issue
(Laudien et al., 2010). TMP-SMX use during RTX maintenance seemed to increase the
risk of hypogammaglobulinemia and RTX discontinuation and to decrease persistent SA
nasal carriage, compared with ciprofloxacin. While TMP-SMX therapy eliminates neither
SA nasal carriage nor endonasal activity in GPA (Laudien et al., 2010), the combination
of TMP-SMX and RTX could provoke changes in the nasal epithelial barrier and its
microbiome that might be relevant for the course of the disease. Moreover, TMP-SMX
could exert an additional anti-inflammatory effect by interfering with the production of
reactive oxygen species in neutrophils (Roberts & Curd, 1990). As TMP-SMX decreases the
risk of relapse (Stegeman et al., 1996), it could, in addition, increase the risk to discontinue
RTX due to hypogammaglobulinemia.
Our retrospective study is limited by its sample size with the low number of events
making subgroups analysis prone to type II errors of not detecting significant differences.
Patients’ selection with multiple relapses and confounding factors, such as high CYC
cumulative dose, could have biased our results and limit their applicability. Despite this,
our study is the first that highlights a possible association between SA carriage status,
infections and hypogammaglobulinemia during RTX therapy in GPA patients.
In conclusion, SA nasal carriage in GPA patients did not change significantly during
long-term RTX maintenance. Non-SA carriers were as likely to have disease flares but
were more prone to infections and to discontinue RTX due to hypogammaglobulinemia
independently of the CYC cumulative dose. These results suggest that long-term RTX
treatment is better tolerated in GPA patients with SA nasal carriage.
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